Latest News in Cancer
Stay updated with the most recent articles and resources.
Main Topics
Tumor Infiltrating lymphocytes (TIL) Immunotherapy in India
Tumor Infiltrating Lymphocytes (TILs) therapy is an experimental cancer treatment that involves harvesting immune cells known as TILs from a patient's tumor, growing them in...
Lesser-known facts about esophageal cancer
April 2023: April month is observed as esophageal cancer awareness month. Esophageal cancer is a type of cancer that affects the esophagus, the muscular tube...
Abemaciclib with endocrine therapy is approved by FDA in HER 2 positive breast cancer
The Food and Drug Administration (FDA) approved abemaciclib (Verzenio, Eli Lilly and Company) with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment...
Sam Neill, “Jurassic Park” actor, has been diagnosed with blood cancer
According to the actor from New Zealand's new biography, he has blood cancer and will require chemotherapy for the rest of his life. But while...
MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer
The goal of this clinical trial is to study the feasibility and efficacy of anti-MESO antigen receptors (CARs) T cell therapy for relapsed and refractory...
A Study of CD19/BCMA CAR-T Cells Therapy for Patients With Refractory Sjogren’s Syndrome
This research focuses on CAR-T cells killing B cells. Sjögren's syndrome (SS) is a systemic autoimmune disease characterized by chronic inflammation of salivary and lachrymal...
Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma
This is an open, single-arm, dose-escalation and multiple-dose study to evaluate the safety, tolerability and preliminary effectiveness of B7-H3-targeting Chimeric Antigen Receptor-T (CAR-T) cell therapy...
A study of chimeric antigen receptor T lymphocytes (CAR-T) in the treatment of relapsed and refractory non-Hodgkin lymphoma
This is a single-center, single-arm, open-label study. After meeting the eligibility criteria and enrolling on the trial, patients will undergo leukapheresis for collection of autologous...
Clinical trial on CAR-T Cell therapy for patients with BCMA/TACI-positive relapsed and/or refractory multiple myeloma
This is a single arm, open-label, single-center study. This study is indicated for relapsed or refractory BCMA/TACI positive relapsed and/or refractory multiple myeloma. The selections...
Anti-BCMA CAR T-Cell therapy clinical trials for relapse/refractory Immune thrombocytopenia(R/R ITP)
This is a prospective, single-center, open-label, single-arm study, to evaluate the efficacy and safety of Anti-BCMA chimeric antigen receptor T cell therapy（BCMA CAR-T）for patients with...
Clinical trial recruitment for BALL CAR T-Cell therapy
This is a phase I, open-label, single-arm study conducted in China to evaluate the safety, tolerability, PK, and determine the recommended phase II dose (RP2D)...
Oricell raises additional $45M USD to expand its CAR T-Cell therapy to United States
Oricell is developing a number of CAR-T therapies and antibody candidates for solid tumors. In the Phase I trial presented at ASCO, a group of...
Need help? Our team is ready to assist you.
We wish a speedy recovery for your loved ones.